Printz, C. (2026). PORTEC‐3 trial finds that adjuvant chemoradiotherapy significantly improves 10‐year survival for patients with high‐risk endometrial cancer. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70063